<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR25">
 <label>25.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>van Tienhoven</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Versteijne</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Suker</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Groothuis</surname>
    <given-names>KBC</given-names>
   </name>
   <name>
    <surname>Busch</surname>
    <given-names>OR</given-names>
   </name>
   <name>
    <surname>Bonsing</surname>
    <given-names>BA</given-names>
   </name>
   <name>
    <surname>de Hingh</surname>
    <given-names>IHJT</given-names>
   </name>
   <name>
    <surname>Festen</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Patijn</surname>
    <given-names>GA</given-names>
   </name>
   <name>
    <surname>de Vos-Geelen</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Zwinderman</surname>
    <given-names>AH</given-names>
   </name>
   <name>
    <surname>Punt</surname>
    <given-names>CJA</given-names>
   </name>
   <name>
    <surname>van Eijck</surname>
    <given-names>CHJ</given-names>
   </name>
   <collab>and all other investigators of the institutions participating in the trial on behalf of the Dutch Pancreatic Cancer Group</collab>
  </person-group>
  <article-title>Preoperative chemoradiotherapy vs immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial</article-title>
  <source>J Clin Oncol</source>
  <year>2018</year>
  <volume>36</volume>
  <issue>18</issue>
  <fpage>LBA4002</fpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2018.36.18_suppl.LBA4002</pub-id>
 </element-citation>
</ref>
